Investing in Equillium (NASDAQ: EQ) carries significant risks, including extreme share price volatility, potential clinical trial failures or delays for its lead drug candidate itolizumab, regulatory hurdles, and the ongoing need for additional funding due to the absence of commercial product revenue. Biotechnology investors face high exposure to binary clinical catalysts that can heavily impact market valuation.